Literature DB >> 33584496

Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis.

Mattia Pozzato1,2, Emanuele Micaglio3, Chiara Starvaggi Cucuzza4, Alessandro Cagol4, Daniela Galimberti5, Daniela Calandrella6, Claudia Cinnante7, Carlo Pappone3, Monica Zanussi8, Giovanni Meola9,10, Elio Scarpini1,5, Nereo Bresolin1,2, Filippo Martinelli Boneschi1,2.   

Abstract

Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disease characterized by recurrent episodes of fever and serositis caused by mutations in the MEFV gene, while Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the CNS with genetic and environmental etiology. The two diseases rarely occur in association with relevant implications for clinical management and drug choice. In this paper, we present the case of a 53-year-old male with an autosomal dominant FMF since childhood who presented acute paresthesia at the right part of the body. He performed a brain and spinal cord MRI, which showed multiple brain lesions and a gd-enhancing lesion in the cervical spinal cord, and then received a diagnosis of MS. He then started Interferonβ-1a which was effective but not tolerated and caused hepatotoxicity, and then shifted to Rituximab with 3-month clinical and neuroradiological efficacy.
Copyright © 2021 Pozzato, Micaglio, Starvaggi Cucuzza, Cagol, Galimberti, Calandrella, Cinnante, Pappone, Zanussi, Meola, Scarpini, Bresolin and Martinelli Boneschi.

Entities:  

Keywords:  case report; familal mediterranean fever; hepatotoxicity; multiple sclerosis; rituximab

Year:  2021        PMID: 33584496      PMCID: PMC7874168          DOI: 10.3389/fneur.2020.591395

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  22 in total

1.  The possible underlying pathophysiological mechanisms for development of multiple sclerosis in familial Mediterranean fever.

Authors:  Mahmut Alpayci; Nazim Bozan; Seyfettin Erdem; Muslum Gunes; Metin Erden
Journal:  Med Hypotheses       Date:  2012-03-10       Impact factor: 1.538

2.  On demand use of anakinra for attacks of familial Mediterranean fever (FMF).

Authors:  Hakan Babaoglu; Ozkan Varan; Hamit Kucuk; Nuh Atas; Hasan Satis; Reyhan Salman; Mehmet Akif Ozturk; Seminur Haznedaroglu; Berna Goker; Abdurrahman Tufan
Journal:  Clin Rheumatol       Date:  2018-07-30       Impact factor: 2.980

Review 3.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

4.  Are carriers for MEFV mutations "healthy"?

Authors:  M Kalyoncu; B C Acar; N Cakar; A Bakkaloglu; S Ozturk; E Dereli; M Tunca; O Kasapcopur; F Yalcinkaya; S Ozen
Journal:  Clin Exp Rheumatol       Date:  2006 Sep-Oct       Impact factor: 4.473

5.  Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity.

Authors:  I Grossman; N Avidan; C Singer; T Paperna; D Lancet; J S Beckmann; A Miller
Journal:  Genes Immun       Date:  2004-09       Impact factor: 2.676

6.  Co-existence of familial Mediterranean fever and multiple sclerosis in two patients.

Authors:  G Ceylan; S Erten; K Ercan
Journal:  Acta Reumatol Port       Date:  2014 Oct-Dec       Impact factor: 1.290

Review 7.  Association between Tumor Necrosis Factor- α-308 G/A Polymorphism and Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Hamidreza Tolide-Ie; Hamid Reza Tabatabaee; Eskandar Kamali-Sarvestani
Journal:  Iran J Med Sci       Date:  2014-01

8.  Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

Authors:  Manabu Araki; Takako Matsuoka; Katsuichi Miyamoto; Susumu Kusunoki; Tomoko Okamoto; Miho Murata; Sachiko Miyake; Toshimasa Aranami; Takashi Yamamura
Journal:  Neurology       Date:  2014-03-14       Impact factor: 9.910

9.  Rituximab Treatment for PR3-ANCA-Positive Membranoproliferative Glomerulonephritis Associated with Adult-Onset Periodic Fever Syndrome.

Authors:  Yoshitomo Hamano; Hiromichi Yoshizawa; Taro Sugase; Takuya Miki; Naoko Ohtani; Shiho Hanawa; Eri Takeshima; Yoshiyuki Morishita; Osamu Saito; Fumi Takemoto; Shigeaki Muto; Wako Yumura; Eiji Kusano
Journal:  Case Rep Nephrol Urol       Date:  2012-07-11

Review 10.  FMF is not always "fever": from clinical presentation to "treat to target".

Authors:  Maria Cristina Maggio; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2020-01-15       Impact factor: 2.638

View more
  1 in total

Review 1.  Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels.

Authors:  Thomas Renson; Lorraine Hamiwka; Susanne Benseler
Journal:  Front Pediatr       Date:  2022-08-10       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.